← Back to Search

MAPK Inhibitor

Binimetinib + Encorafenib for Recurrent Brain Cancer (BRAF Trial)

Phase 2
Waitlist Available
Led By Karisa C Schreck, MD
Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must be 18 years of age or older.
Patients must be able to swallow tablets and capsules.
Screening 3 weeks
Treatment Varies
Follow Up up to 3 year
Awards & highlights

BRAF Trial Summary

This trial is testing a new combination of drugs to see if it can shrink tumors in people with a type of brain cancer that has come back.

Who is the study for?
Adults with recurrent high-grade brain tumors and BRAF V600 mutation can join. They must be over 18, have measurable disease by MRI, good organ function, no severe neuromuscular disorders or uncontrolled infections like HIV/Hepatitis B/C (with exceptions), not on certain medications, able to swallow pills, and agree to contraception. Those with other cancers must be disease-free for 2 years.Check my eligibility
What is being tested?
The trial is testing the effectiveness of two drugs—Encorafenib and Binimetinib—in treating recurrent brain tumors by observing changes in tumor size through MRI scans. Participants will take these oral medications under specific conditions regarding prior treatments and health status.See study design
What are the potential side effects?
Potential side effects include muscle pain or weakness (myopathy), inflammation of the pancreas (pancreatitis), blocked blood vessels in the eye (retinal vein occlusion), liver issues due to Hepatitis B/C reactivation, skin reactions at drug application sites, increased risk of infection from HIV/Hepatitis B/C.

BRAF Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am 18 years old or older.
I can swallow pills.
I am mostly able to care for myself but may need occasional help.

BRAF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Tumor Radiographic Response Per RANO for 3 Treatment Cohorts
Secondary outcome measures
Duration of Response - Complete and Partial
Number of Participants With Adverse Events as Defined by Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0)
Overall Survival
+1 more

BRAF Trial Design

4Treatment groups
Experimental Treatment
Group I: Treatment Cohort 3 Other TumorsExperimental Treatment4 Interventions
Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle Research Bloods
Group II: Treatment Cohort 2 anaplastic PXAsExperimental Treatment4 Interventions
Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle Research Bloods
Group III: Treatment Cohort 1 AA & GBMExperimental Treatment4 Interventions
Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle Research Bloods
Group IV: Surgical ArmExperimental Treatment4 Interventions
Pre-op -14 days: Encorafenib 450mg QD and Binimetinib 45mg BID last dose of both drugs 2hrs prior to surgery Tumor; research blood; CSF samples post surgery: Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3
Completed Phase 3
Tumor Tissue

Find a Location

Who is running the clinical trial?

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
561 Previous Clinical Trials
33,078 Total Patients Enrolled
2 Trials studying Gliosarcoma
76 Patients Enrolled for Gliosarcoma
National Cancer Institute (NCI)NIH
13,732 Previous Clinical Trials
40,967,833 Total Patients Enrolled
142 Trials studying Gliosarcoma
10,814 Patients Enrolled for Gliosarcoma
PfizerIndustry Sponsor
4,587 Previous Clinical Trials
14,637,817 Total Patients Enrolled
1 Trials studying Gliosarcoma
23 Patients Enrolled for Gliosarcoma

Media Library

Binimetinib (MAPK Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03973918 — Phase 2
Gliosarcoma Research Study Groups: Surgical Arm, Treatment Cohort 1 AA & GBM, Treatment Cohort 2 anaplastic PXAs, Treatment Cohort 3 Other Tumors
Gliosarcoma Clinical Trial 2023: Binimetinib Highlights & Side Effects. Trial Name: NCT03973918 — Phase 2
Binimetinib (MAPK Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03973918 — Phase 2
~1 spots leftby Jun 2025